GE Healthcare Alters China Strategy, Faces Off With Domestic Companies
This article was originally published in PharmAsia News
GE Healthcare recently caught domestic medical device companies off guard when it announced a series of ambitious projects in China, including a financing program to address potential hospital funding gaps
You may also be interested in...
The approval is based on the results ABRE clinical study, which showed the stent improved patency iliofemoral veins in 88% of cases with a 2% rate of major adverse events.
Reporting its first full quarter of financials since merging with Allergan, AbbVie will be scrutinized for whether its optimistic talk of a quick Botox rebound actually happened.
Generic OTC paracetamol and ibuprofen pack prices are gradually returning to pre-COVID levels, according to market analysts Wavedata. But a second wave could drive prices back up again.